NEUROTROPE BIOSCIENCE is a biopharmaceutical company focused on developing Bryostatin for the treatment of advanced Alzheimer’s Disease. Over many years, in pre-clinical and compassionate use trials, Bryostatin has shown a unique ability to arrest the ongoing process of neurodegeneration and, in some cases, reverse this process leading to the restoration of nerve cell function. In its initial Phase 2 trial, completed in 2017, Neurotrope identified the optimal (low) dose and necessary patient exclusion criteria and plans to begin a confirmatory Phase 2 trial in 2018.